Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 10 versus AMINOSYN HBC 7 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 10 versus AMINOSYN HBC 7 IN PLASTIC CONTAINER.
AMINOSYN 10% vs AMINOSYN-HBC 7% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 10% provides a mixture of essential and non-essential amino acids to support protein synthesis and maintain nitrogen balance in patients unable to tolerate adequate oral or enteral nutrition. Each amino acid serves as a substrate for protein synthesis, hormone production, and other metabolic processes.
Provides essential and nonessential amino acids to support protein synthesis and nitrogen balance in patients with metabolic stress or hepatic encephalopathy.
Intravenous infusion: 1-1.5 g/kg/day (as amino acids), typically 500 mL of 10% solution (50 g amino acids) over 8-12 hours daily.
1-2 L/day intravenously (equivalent to 70-140 g amino acids/day) for adults; infuse at no more than 0.1 g/kg/h.
None Documented
None Documented
Amino acids: 0.5-1 hour for free amino acids; terminal half-life of infused nitrogen is approximately 2-4 hours; clinical context: reflects rapid uptake and metabolism.
Terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for free amino acids, but varies by individual amino acid. Clinical context: rapid clearance in critically ill patients due to increased metabolic demand.
Renal (primarily as amino acids and metabolites); ~90% of infused amino nitrogen is excreted renally within 24-48 hours; <5% biliary/fecal.
Renal: 100% of infused amino acids are metabolized or excreted renally as urea and other nitrogenous waste products. No biliary or fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution